LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

Search

Krystal Biotech Inc

Geschlossen

BrancheGesundheitswesen

233.8 5.45

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

228.96

Max

233.8

Schlüsselkennzahlen

By Trading Economics

Einkommen

41M

79M

Verkäufe

1.8M

98M

KGV

Branchendurchschnitt

32.25

80.03

Gewinnspanne

81.15

Angestellte

275

EBITDA

10M

50M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

-5.29% downside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

741M

6.2B

Vorheriger Eröffnungskurs

228.35

Vorheriger Schlusskurs

233.8

Nachrichtenstimmung

By Acuity

26%

74%

50 / 374 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Krystal Biotech Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

5. Dez. 2025, 21:08 UTC

Akquisitionen, Fusionen, Übernahmen

Meta Platforms Buys AI-Device Maker Limitless

5. Dez. 2025, 19:39 UTC

Wichtige Markttreiber

Parsons' FAA Bid Loss Clouds Outlook After Rocky Year for Contractors

5. Dez. 2025, 19:17 UTC

Akquisitionen, Fusionen, Übernahmen

Constellation Energy Agrees to Divest Assets to Finalize Calpine Deal

6. Dez. 2025, 16:52 UTC

Akquisitionen, Fusionen, Übernahmen

As Netflix Swoops In to Buy Warner Bros., We Revisit the Studio's Long, Twisted Journey -- Barrons.com

6. Dez. 2025, 10:30 UTC

Akquisitionen, Fusionen, Übernahmen

Why Netflix Shareholders Aren't Thrilled to Acquire Warner Bros. -- Heard on the Street -- WSJ

6. Dez. 2025, 02:38 UTC

Akquisitionen, Fusionen, Übernahmen

How a Netflix-Warner Deal Would Change Everything in Hollywood -- Again -- WSJ

5. Dez. 2025, 21:59 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix's Megadeal Will Need the Trump Administration's Blessing -- Update

5. Dez. 2025, 21:50 UTC

Market Talk
Ergebnisse

Financial Services Roundup: Market Talk

5. Dez. 2025, 21:50 UTC

Akquisitionen, Fusionen, Übernahmen

The Netflix and Warner Bros. Deal Is Far From a Sure Thing -- Barrons.com

5. Dez. 2025, 21:36 UTC

Market Talk

Return of Shipping to Red Sea a Step Closer, Xeneta Says -- Market Talk

5. Dez. 2025, 21:35 UTC

Akquisitionen, Fusionen, Übernahmen

The Netflix-Warner Bros. Deal Has a Wildcard. How Paramount Could Still Win. -- Barrons.com

5. Dez. 2025, 21:26 UTC

Akquisitionen, Fusionen, Übernahmen

Warner Bros. Discovery and Netflix Enter Exclusive Deal Negotiations -- 7th Update

5. Dez. 2025, 21:12 UTC

Market Talk

Natural Gas Surge 9% This Week on Strong Flow of Exports -- Market Talk

5. Dez. 2025, 21:03 UTC

Market Talk
Ergebnisse

Bank of Montreal Logs Solid Quarter, Though Some Unease Remains -- Market Talk

5. Dez. 2025, 21:01 UTC

Market Talk

Oil Caps Positive Week on Geopolitical Turmoil -- Market Talk

5. Dez. 2025, 20:43 UTC

Akquisitionen, Fusionen, Übernahmen

Limitless CEO Siroker: Will No Longer Sell Pendant to New Customers

5. Dez. 2025, 20:43 UTC

Akquisitionen, Fusionen, Übernahmen

Limitless CEO Siroker: Existing Pendant Customers to Be Supported for at Least Another Year

5. Dez. 2025, 20:42 UTC

Akquisitionen, Fusionen, Übernahmen

Limitless CEO Dan Siroker: Limitless Has Been Acquired by Meta >META

5. Dez. 2025, 20:01 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix Landed a Big Deal. Now it Could Have a Big Fight. -- WSJ

5. Dez. 2025, 19:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5. Dez. 2025, 19:44 UTC

Market Talk

Canada Dollar Gains Nearly 1% on Jobs Data, Rate Outlook -- Market Talk

5. Dez. 2025, 19:39 UTC

Market Talk

Silver Climbs to a New Record High -- Market Talk

5. Dez. 2025, 19:31 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5. Dez. 2025, 18:30 UTC

Market Talk

Canada Jobless Rate Can Fall More Before Labor Slack Disappears -- Market Talk

5. Dez. 2025, 18:28 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5. Dez. 2025, 18:24 UTC

Akquisitionen, Fusionen, Übernahmen

AMC and IMAX Stocks Drop. Roku Rises. How the Netflix-Warner Bros. Deal Could Shake Up Entertainment. -- Barrons.com

5. Dez. 2025, 18:20 UTC

Market Talk

Baker Hughes Reports Higher U.S. Rig Count -- Market Talk

5. Dez. 2025, 18:11 UTC

Market Talk

The Tale of Two Canadian Employment Indicators -- Market Talk

5. Dez. 2025, 17:48 UTC

Market Talk

Canadian Youth Unemployment Rate Cools -- Market Talk

5. Dez. 2025, 17:44 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Global Equities Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Krystal Biotech Inc Prognose

Kursziel

By TipRanks

-5.29% Nachteil

12-Monats-Prognose

Durchschnitt 221.75 USD  -5.29%

Hoch 255 USD

Tief 198 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Krystal Biotech Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

9 ratings

8

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

133.221 / 169.73Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Strong Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

50 / 374 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
help-icon Live chat